Eris Lifesciences Limited (ERIS.NS)
INR 1401.3
(0.86%)
INR 1401.3
(0.86%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.15 Billion | 2.91 Billion | 3.78 Billion | 3.75 Billion | 2.71 Billion | 2.22 Billion |
| Net Income | 3.91 Billion | 4.04 Billion | 4.42 Billion | 3.94 Billion | 3.31 Billion | 3.17 Billion |
| Depreciation & Amortization | 1.82 Billion | 1.17 Billion | 647.05 Million | 429.85 Million | 502.58 Million | 363.54 Million |
| Deferred income taxes | - | -809.69 Million | -976.58 Million | -670.94 Million | -585.06 Million | -980.19 Million |
| Stock-based compensation | 32.86 Million | 31.21 Million | 13.55 Million | 11.2 Million | 16.61 Million | 16.52 Million |
| Change in working capital | -987.39 Million | -1.75 Billion | -299.01 Million | 53.27 Million | -527.06 Million | -532.38 Million |
| Other non-cash items | 2.88 Billion | 233.91 Million | -24.35 Million | -14.74 Million | -9.47 Million | 188.89 Million |
| Investing Cash Flow | -18.71 Billion | -9.82 Billion | -3.19 Billion | -3.23 Billion | 1.23 Billion | -50.51 Million |
| Investments in PPE | -1.29 Billion | -8.41 Billion | -1.21 Billion | -257.63 Million | -1.51 Billion | -380.02 Million |
| Acquisitions | -5.77 Billion | -6.55 Billion | -102.95 Million | -2.81 Million | -213.73 Million | -30.73 Million |
| Investment purchases | -12.12 Billion | -300 Million | -2.67 Billion | -3.73 Billion | -381 Million | -447.67 Million |
| Sales/Maturities of investments | 484.06 Million | 5.2 Billion | 795.87 Million | 774.2 Million | 3.26 Billion | 797.3 Million |
| Other Investing Activities | -16.51 Million | 243.72 Million | -960 Thousand | -13.42 Million | 79.64 Million | 10.61 Million |
| Financing Cash Flow | 14.67 Billion | 6.88 Billion | -446.99 Million | -823.95 Million | -3.34 Billion | -2.21 Billion |
| Debt repayment | -14.63 Billion | -3.5 Billion | -450.01 Million | -100 Thousand | -1.75 Billion | -2 Billion |
| Dividends payments | - | -999.11 Million | -816.23 Million | -746.79 Million | -469.79 Million | - |
| Common Stock Repurchased | - | 3.47 Billion | -450.01 Million | - | -1.01 Billion | - |
| Common Stock Issuance | 45.43 Million | 22.78 Million | 67.45 Million | - | 2.85 Billion | 8.92 Million |
| Other Financing Activities | -102.8 Million | 7.87 Billion | 1.2 Billion | -77.06 Million | -2.95 Billion | -217.31 Million |
| Accounts receivables | -570.93 Million | -1.17 Billion | -204.8 Million | 158.96 Million | -747.86 Million | -175.54 Million |
| Accounts payables | 909.78 Million | -104.97 Million | 151.59 Million | 25.66 Million | 159.34 Million | 55.09 Million |
| Inventory | -169.4 Million | 47.44 Million | -234.45 Million | -249.91 Million | 131.78 Million | -172.05 Million |
| Other working capital | -1.15 Billion | -526.45 Million | -11.35 Million | 118.56 Million | -70.32 Million | -239.88 Million |
| Cash at beginning of period | 560.22 Million | 508.7 Million | 369.15 Million | 673.07 Million | 75 Million | 106.08 Million |
| Cash at end of period | 14 Billion | 560.22 Million | 508.7 Million | 369.15 Million | 673.07 Million | 75 Million |
| Capital Expenditure | -1.29 Billion | -8.41 Billion | -1.21 Billion | -257.63 Million | -1.51 Billion | -380.02 Million |
| Effect of forex changes on cash | - | 74.9 Million | - | - | - | - |
| Net cash flow / Change in cash | 13.44 Billion | 51.52 Million | 139.55 Million | -303.92 Million | 598.07 Million | -31.08 Million |
| Free Cash Flow | 2.86 Billion | -5.49 Billion | 2.57 Billion | 3.49 Billion | 1.19 Billion | 1.84 Billion |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 831.8 Million | 3.91 Billion | 709.62 Million | 1.02 Billion | 1.23 Billion | 948.55 Million |
| Depreciation & Amortization | - | 1.82 Billion | - | 457.16 Million | 420.94 Million | 408.94 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 7.5 Million | - | - | - | - |
| Change in working capital | - | -987.39 Million | - | - | - | - |
| Other non-cash items | -831.8 Million | 2.88 Billion | -709.62 Million | -1.02 Billion | -1.23 Billion | -948.55 Million |
| Investing Cash Flow | - | -18.71 Billion | - | - | - | - |
| Investments in PPE | - | -1.29 Billion | - | - | - | - |
| Acquisitions | - | -5.77 Billion | - | - | - | - |
| Investment purchases | - | -12.12 Billion | - | - | - | - |
| Sales/Maturities of investments | - | 484.06 Million | - | - | - | - |
| Other Investing Activities | - | -16.51 Million | - | - | - | - |
| Financing Cash Flow | - | 14.67 Billion | - | - | - | - |
| Debt repayment | - | -14.63 Billion | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 45.43 Million | - | - | - | - |
| Other Financing Activities | - | -102.8 Million | - | - | - | - |
| Accounts receivables | - | -570.93 Million | - | - | - | - |
| Accounts payables | - | 909.78 Million | - | - | - | - |
| Inventory | - | -169.4 Million | - | - | - | - |
| Other working capital | - | -1.15 Billion | - | - | - | - |
| Cash at beginning of period | - | 560.22 Million | - | 1.72 Billion | 885.26 Million | 560.22 Million |
| Cash at end of period | - | 14 Billion | - | 2.64 Billion | 1.72 Billion | 1.37 Billion |
| Capital Expenditure | - | -1.29 Billion | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | 13.44 Billion | - | 914.32 Million | 841.88 Million | 817.88 Million |
| Free Cash Flow | - | 2.86 Billion | - | 914.32 Million | 841.88 Million | 817.88 Million |
IFP
CITY
RSP
ABSO
603808
EGYF